Navigation Links
Generex Announces Date of Annual Stockholders' Meeting
Date:4/23/2012

WORCESTER, Mass. and TORONTO, April 23, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the next annual meeting of the Generex stockholders will be held at 10 a.m. EDT on Tuesday, June 19, 2012.  The meeting will be held at the Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Ontario, Canada.  The record date for the meeting is May 2, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
2. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
3. Generex Secures Commitments for $3.6M Capital Raise
4. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
5. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
6. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
7. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
8. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
9. Generex Provides Update on Spinout of Antigen Express
10. Generex Augments Cash Position With Sales of Non-Essential Assets
11. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Sodium ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... China Acetic Acid Industry" is a professional and ... and Global Acetic Acid Market. The report ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... HARBOR, Mich. , Sept. 18, 2014  Health Enhancement ... biotech firm investigating early-stage algae bioactive compounds and metabolic processes, ... to the company,s board of directors. Ms. Nola E. ... and investment advisor joined the board effective September 17, 2014. ... Ms. Masterson agree to join our board," states Andrew ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... LIVINGSTON and PARSIPPANY, N.J., Jan. 20, 2012 Columbia ... Pharmaceuticals, Inc. (NYSE: WPI ), today confirmed ... the U.S. Food and Drug Administration (FDA) did not ... reduction of risk of preterm birth in women with ...
... Boulder Diagnostics Inc. and Portland State University (PSU) ... agreement to develop rapid diagnostic tests for homocysteine and ... developed at PSU. Under the agreement Boulder will finance ... will be entitled to royalties on future sales of ...
... Mellon University researchers have discovered that an element commonly found ... lethal effects of a compound known as Shiga toxin. New ... by Carnegie Mellon biologists Adam Linstedt and Somshuvra Mukhopadhyay ... models. Produced by certain bacteria, including ...
Cached Biology Technology:FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length 2FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length 3FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length 4FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length 5Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University 2Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin 2Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin 3Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin 4
(Date:9/18/2014)... circuit located deep in the primitive brainstem has revealed ... at Harvard School of Medicine and the University at ... only the second "sleep node" identified in the mammalian ... sufficient to produce deep sleep. , Published online in ... that fully half of all of the brain,s sleep-promoting ...
(Date:9/18/2014)... Miranda, a small, icy moon of Uranus, is ... in the solar system. Despite its relatively small size, ... resurfacing that resulted in the formation of at least ... called coronae. , These coronae are visible in ... 200 km across. Arden corona, the largest, has ridges ...
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Research milestone in CCHF virus could help identify new treatments 2
... Institute have deciphered the structure of the active region ... in the development of nearly all human cancers. The ... new, broadly effective cancer drugs, as well as anti-aging ... decade to find drugs that shut down telomerasewidely considered ...
... the Alliance for a Healthier Generation and the American ... such as soft drinks at schools. However, researchers at ... soft drinks at school may not be enough to ... a study of more than 4,000 children, the researchers ...
... during cardiac procedures. Doctors performing heart surgery also face ... is helping to raise awareness of threats, through training ... imaging systems. The issue of radiation protection for ... lengthy angioplasty and other cardiac interventions performed under X-ray ...
Cached Biology News:Landmark study opens door to new cancer, aging treatments 2Landmark study opens door to new cancer, aging treatments 3Protecting those who heal 2
... polyclonal to ErbB 2 - BSA ... for all tested applications). ... conjugated to KLH, corresponding to C ... c-ErbB2 Entrez GeneID: ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
Biology Products: